The global viral clearance market size was estimated to be USD 0.502 billion in 2023 and is expected to reach at USD 1.25 billion by 2034 with a CAGR of 8.67% during the forecast period 2024-2034. Increase in biosimilar approvals, a surge in research and development activities, heightened investment by key market players, a growing emphasis on advanced service development, a rise in mergers and acquisitions, an increased focus on novel product development, growing demand in the pharmaceutical and biotechnological industries, and an uptick in the number of new drug releases are some of the key factors boosting the market growth.
Viral clearance plays a crucial role in the development of monoclonal antibodies, recombinant proteins, glycoproteins, as well as tissue and blood-derived products, along with medical devices. Viral contamination poses a universal risk to both animal- and human-derived biopharmaceuticals. Given that this form of contamination can impact various stages of the bioproduction process, biomanufacturers must conduct viral testing studies and integrate viral clearance methods into their procedures to mitigate potential risks. Hence, market players are focusing on mergers & acquisitions which is anticipated to boost the market growth during the forecast period. For instance, In June 2022, Asahi Kasei Medical is entering the Contract Development and Manufacturing Organization (CDMO) sector through the acquisition of Bionova Scientific, a biologics manufacturer based in the Bay Area, for an undisclosed amount. Reflecting a trend seen across the industry, Asahi Kasei, headquartered in Japan, has been actively expanding its operations in recent years.
By method, viral removal was the highest revenue-grossing segment in the global viral clearance market in 2023 owing to the expansion of research and development (R&D) endeavors by biopharmaceutical companies, widespread adoption of this methodology, and the method's notable attributes such as accuracy, speed, and flexibility in life sciences research are driving significant advancements in the field. Additionally, viral inactivation is predicted to boost the market growth during the forecast period owing to the rising number of approvals for new vaccines and therapeutics, coupled with a growing demand for innovative products like plasma proteins and gene therapy products, is contributing to notable developments in the healthcare sector. For instance, in March 2023, GTP Bioways, a Contract Development and Manufacturing Organization (CDMO) focused on biotherapeutics manufacturing, and Texcell, a Contract Research Organization (CRO) specialized in viral safety, assay development, and Good Manufacturing Practice (GMP) banking, have collaborated to offer integrated services to biopharmaceutical companies. GTP Bioways specializes in biologic manufacturing, while Texcell specializes in viral testing, viral clearance, and bioassays. This partnership aims to provide a comprehensive solution for biopharmaceutical companies, offering testing and manufacturing support during clinical development.
By application, recombinant proteins was the highest revenue-grossing segment in the global viral clearance market in 2023 owing to the increase in the prevalence of chronic diseases, coupled with a rise in global government funding for research and development (R&D) activities. Additionally, others is predicted to boost the market growth during the forecast period owing to the growing adoption of cellular therapies for treating diverse disorders, heightened awareness regarding stem cell therapies, the application of tissue-based therapies for various diseases, and an increase in both public and private funding for research are contributing to significant advancements in the field. For instance, in June 2023, Cytiva and BioCentriq have received a funding of USD 15.8 million from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The purpose of this funding is to advance the development of a platform for Viral And Exotoxin Clearance in the manufacturing process of adeno-associated virus (AAV).
By end-user, pharmaceutical and biotechnology companies was the highest revenue-grossing segment in the global viral clearance market in 2023 owing to the heightened utilization of viral clearance processing in the biopharmaceutical production, increased investments in research and development, and strategic initiatives such as collaborations adopted by key market players. For instance, in June 2023, Valo Therapeutics has partnered with Texcell to explore immune responses to PeptiCRAd-1 as part of its Phase 1 clinical study. Additionally, contract research organizations is predicted to boost the market growth during the forecast period owing to CROs have the capacity to invest in substantial drug discovery infrastructure, and there is a growing trend of pharmaceutical companies, academic institutes, small biotechnology firms, and start-ups outsourcing Drug Discovery Services to these CROs.
North America region is anticipated for the highest revenue share during the forecast period owing to the backing of national institutes for biotechnology and life science research, the expansion of the pharmaceutical industry, a rise in drug approvals, an increasing incidence of diseases, a heightened production of monoclonal antibodies, government encouragement for drug development, and the escalating production in the pharmaceutical sector. For instance, in June 2023, Texcell has declared the establishment of a testing facility in North America, with the goal of enhancing the viral safety assessment for biotherapeutics and medical devices. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to an uptick in the development and manufacturing of generics, a surge in funding for medical research, the abundance of Contract Research Organizations (CROs) offering preclinical and clinical research services, government initiatives promoting the use of generic drugs, a growing aging population, an increase in expenditures for pharmaceutical research and development (R&D), and the expansion of pharmaceutical manufacturing. For instance, in September 2022, MilliporeSigma has inaugurated a biologics testing center in Shanghai, China, featuring a dedicated viral clearance laboratory. This facility is established to address the increasing local demand for viral clearance testing services.
Viral clearance plays a crucial role in the development of monoclonal antibodies, recombinant proteins, glycoproteins, as well as tissue and blood-derived products, along with medical devices. Viral contamination poses a universal risk to both animal- and human-derived biopharmaceuticals. Given that this form of contamination can impact various stages of the bioproduction process, biomanufacturers must conduct viral testing studies and integrate viral clearance methods into their procedures to mitigate potential risks. Hence, market players are focusing on mergers & acquisitions which is anticipated to boost the market growth during the forecast period. For instance, In June 2022, Asahi Kasei Medical is entering the Contract Development and Manufacturing Organization (CDMO) sector through the acquisition of Bionova Scientific, a biologics manufacturer based in the Bay Area, for an undisclosed amount. Reflecting a trend seen across the industry, Asahi Kasei, headquartered in Japan, has been actively expanding its operations in recent years.
By method, viral removal was the highest revenue-grossing segment in the global viral clearance market in 2023 owing to the expansion of research and development (R&D) endeavors by biopharmaceutical companies, widespread adoption of this methodology, and the method's notable attributes such as accuracy, speed, and flexibility in life sciences research are driving significant advancements in the field. Additionally, viral inactivation is predicted to boost the market growth during the forecast period owing to the rising number of approvals for new vaccines and therapeutics, coupled with a growing demand for innovative products like plasma proteins and gene therapy products, is contributing to notable developments in the healthcare sector. For instance, in March 2023, GTP Bioways, a Contract Development and Manufacturing Organization (CDMO) focused on biotherapeutics manufacturing, and Texcell, a Contract Research Organization (CRO) specialized in viral safety, assay development, and Good Manufacturing Practice (GMP) banking, have collaborated to offer integrated services to biopharmaceutical companies. GTP Bioways specializes in biologic manufacturing, while Texcell specializes in viral testing, viral clearance, and bioassays. This partnership aims to provide a comprehensive solution for biopharmaceutical companies, offering testing and manufacturing support during clinical development.
By application, recombinant proteins was the highest revenue-grossing segment in the global viral clearance market in 2023 owing to the increase in the prevalence of chronic diseases, coupled with a rise in global government funding for research and development (R&D) activities. Additionally, others is predicted to boost the market growth during the forecast period owing to the growing adoption of cellular therapies for treating diverse disorders, heightened awareness regarding stem cell therapies, the application of tissue-based therapies for various diseases, and an increase in both public and private funding for research are contributing to significant advancements in the field. For instance, in June 2023, Cytiva and BioCentriq have received a funding of USD 15.8 million from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The purpose of this funding is to advance the development of a platform for Viral And Exotoxin Clearance in the manufacturing process of adeno-associated virus (AAV).
By end-user, pharmaceutical and biotechnology companies was the highest revenue-grossing segment in the global viral clearance market in 2023 owing to the heightened utilization of viral clearance processing in the biopharmaceutical production, increased investments in research and development, and strategic initiatives such as collaborations adopted by key market players. For instance, in June 2023, Valo Therapeutics has partnered with Texcell to explore immune responses to PeptiCRAd-1 as part of its Phase 1 clinical study. Additionally, contract research organizations is predicted to boost the market growth during the forecast period owing to CROs have the capacity to invest in substantial drug discovery infrastructure, and there is a growing trend of pharmaceutical companies, academic institutes, small biotechnology firms, and start-ups outsourcing Drug Discovery Services to these CROs.
North America region is anticipated for the highest revenue share during the forecast period owing to the backing of national institutes for biotechnology and life science research, the expansion of the pharmaceutical industry, a rise in drug approvals, an increasing incidence of diseases, a heightened production of monoclonal antibodies, government encouragement for drug development, and the escalating production in the pharmaceutical sector. For instance, in June 2023, Texcell has declared the establishment of a testing facility in North America, with the goal of enhancing the viral safety assessment for biotherapeutics and medical devices. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to an uptick in the development and manufacturing of generics, a surge in funding for medical research, the abundance of Contract Research Organizations (CROs) offering preclinical and clinical research services, government initiatives promoting the use of generic drugs, a growing aging population, an increase in expenditures for pharmaceutical research and development (R&D), and the expansion of pharmaceutical manufacturing. For instance, in September 2022, MilliporeSigma has inaugurated a biologics testing center in Shanghai, China, featuring a dedicated viral clearance laboratory. This facility is established to address the increasing local demand for viral clearance testing services.
Segmentation: Viral Clearance Market Report 2023 - 2034
Viral Clearance Market Analysis & Forecast by Method 2023 - 2034 (Revenue USD Bn)
- Solvent Detergent Method
- Pasteurization
- Chromatography
- Precipitation
- Viral Inactivation
- Viral Removal
- Nanofiltration
- Low pH
- Other Viral Inactivation Methods
Viral Clearance Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Blood and Blood Products
- Recombinant Proteins
- Vaccines
- Others
Viral Clearance Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- Academic Research Institutes
- Others
Viral Clearance Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Viral Clearance Market: Material Estimates & Trend Analysis
8. Viral Clearance Market: Application Estimates & Trend Analysis
9. Viral Clearance Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Viral Clearance Market
12. Europe Global Viral Clearance Market
13. Asia Pacific Global Viral Clearance Market
14. Latin America Global Viral Clearance Market
15. MEA Global Viral Clearance Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Charles River Laboratories International Inc.
- Maravai Lifesciences Holdings Inc.
- Allure Medical Group
- Sartorius Stedim Biotech
- Clean Cells
- Wuxi Biologics Inc.
- Eurofins Scientific Se
- Merck Kgaa
- Creative Biogene
- Syngene International Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.5 Billion |
| Forecasted Market Value ( USD | $ 1.25 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
